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With the goal of identifying genes with a differential pat-
tern of expression between ovarian serous papillary carcino-
mas (OSPCs) and normal ovarian (NOVA) epithelium and
using this knowledge for the development of novel diagnostic
and therapeutic markers for ovarian cancer, we used oligo-
nucleotide microarrays with probe sets complementary to
12,533 genes to analyze the gene expression proﬁles of 10
primary OSPC cell lines, 2 established OSPC cell lines (UCI-
101, UCI-107) and 5 primary NOVA epithelial cultures. Un-
supervised analysis of gene expression data identiﬁed 129 and
170 genes that exhibited >5-fold upregulation and downregu-
lation, respectively, in primary OSPC compared to NOVA.
Genes overexpressed in established OSPC cell lines had little
correlation with those overexpressed in primary OSPC, high-
lighting the divergence of gene expression that occurs as a
result of long-term in vitro growth. Hierarchical clustering of
the expression data readily distinguished normal tissue from
primary OSPC. Laminin, claudin 3, claudin 4, tumor-associated
calcium signal transducers 1 and 2 (TROP-1/Ep-CAM, TROP-2),
ladinin 1, S100A2, SERPIN2 (PAI-2), CD24, lipocalin 2, osteopon-
tin, kallikrein 6 (protease M), kallikrein 10, matriptase (TADG-
15) and stratifin were among the most highly overexpressed
genes in OSPC compared to NOVA. Downregulated genes in
OSPC included transforming growth factor- receptor III, plate-
let-derived growth factor receptor , SEMACAP3, ras homolog
gene family member I (ARHI), thrombospondin 2 and disabled-
2/differentially expressed in ovarian carcinoma 2 (Dab2/DOC2).
Differential expression of some of these genes, including clau-
din 3, claudin 4, TROP-1 and CD24, was validated by quanti-
tative RT-PCR and flow cytometry on primary OSPC and
NOVA. Immunohistochemical staining of formalin-ﬁxed,
parafﬁn-embedded tumor specimens from which primary
OSPC cultures were derived further conﬁrmed differential
expression of CD24 and TROP-1/Ep-CAM markers on OSPC
vs. NOVA. These results, obtained with highly puriﬁed pri-
mary cultures of ovarian cancer, highlight important molec-
ular features of OSPC and may provide a foundation for the
development of new type-speciﬁc therapies against this dis-
ease.
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Ovarian carcinoma remains the cancer with the highest mortal-
ity rate among gynecologic malignancies, with 25,400 new cancer
cases estimated in 2003 in the United States alone.1 OSPC repre-
sents the most common histologic type of ovarian carcinoma.2
Because of the insidious onset of the disease and the lack of
reliable screening tests, two-thirds of patients have advanced dis-
ease when diagnosed; and although many patients with dissemi-
nated tumors respond initially to standard combinations of surgical
and cytotoxic therapy, nearly 90% will develop recurrence and
inevitably succumb to their disease.2 Understanding the molecular
basis of OSPC may signiﬁcantly reﬁne the diagnosis and manage-
ment of these tumors and may eventually lead to the development
of novel, more speciﬁc and more effective treatment modalities.
cDNA microarray technology has been used to identify genes
involved in ovarian carcinogenesis.3–11 Gene expression ﬁnger-
prints representing large numbers of genes may allow precise and
accurate grouping of human tumors and may identify patients who
are unlikely to be cured by conventional therapy. Consistent with
this view, evidence has been provided to support the notion that
poor-prognosis B-cell lymphomas and biologically aggressive
breast and ovarian carcinomas can be readily distinguished by
gene expression proﬁles.4,12,13 In addition, large-scale gene expres-
sion analysis has the potential to identify a number of differentially
expressed genes in OSPC compared to NOVA epithelial cells and
may therefore lay the groundwork for future studies of some of
these markers for clinical utility in the diagnosis and treatment of
OSPC.
Expression proﬁling studies involve the comparison of OSPC
cells with their normal counterpart. However, selection of NOVA
control cells may strongly inﬂuence the determination of differen-
tially expressed genes in ovarian cancer expression proﬁling stud-
ies.14 In this regard, because ovarian epithelial cells constitute only
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a small proportion of the total cells found in NOVA samples and
because ovarian tumor tissue contains signiﬁcant numbers of con-
taminant stromal cells as well as a variety of host-derived immune
cells (e.g., monocytes, dendritic cells, lymphocytes), we used
oligonucleotide microarrays with probe sets complementary to
12,533 genes to analyze the gene expression proﬁles in primary
OSPC cultures and NOVA epithelium cell lines. Short-term pri-
mary OSPC and NOVA cell cultures, minimizing the risk of
selection bias inherent in any long-term in vitro growth, may
provide an opportunity to study differential gene expression be-
tween relatively pure populations of tumor- and NOVA-derived
epithelial cells.
We report that mRNA ﬁngerprints readily distinguish OSPC
from NOVA epithelial cells and identify a number of genes highly
differentially expressed between nontransformed ovarian epithelia
and OSPC. Several of the genes identiﬁed are already known to be
overexpressed in ovarian cancer, validating our experimental ap-
proach as well as our criteria to determine the genes differentially
expressed; but several represent novel ﬁndings. Of interest, many
of the genes upregulated in ovarian cancer represent surface or
secreted proteins, such as laminin, claudin 3, claudin 4, tumor-
associated calcium signal transducers 1 and 2 (TROP-1/Ep-CAM,
TROP-2), ladinin 1, S100A2, SERPIN2 (PAI-2), CD24, lipocalin
2, osteopontin, kallikrein 6 (protease M), kallikrein 10, matriptase
(TADG-15) and stratiﬁn. Quantitative real-time PCR was used to
validate differences in gene expression between nontransformed
ovarian epithelia and OSPC for some of these genes, including
TROP-1/Ep-CAM, CD24, claudin 3 and claudin 4. TROP-1/Ep-
CAM and CD24 gene expression was further validated through
ﬂow-cytometric analysis of primary OSPC and NOVA as well as
by immunohistochemical analysis of archival OSPC and NOVA
specimens.
MATERIALS AND METHODS
Establishment of OSPC and NOVA primary cell lines
A total of 15 primary cell lines (10 OSPC and 5 NOVA) were
established after sterile processing of samples from surgical biop-
sies, as previously described for ovarian carcinoma speci-
mens.3,6,15 UCI-101 and UCI-107, 2 previously characterized
OSPC cell lines,16,17 were also included. All fresh tumor samples
were obtained with appropriate consent according to institutional
review board guidelines. Tumors were staged according to the
FIGO operative staging system. Radical tumor debulking, includ-
ing total abdominal hysterectomy and omentectomy, was per-
formed in all ovarian carcinoma patients, while NOVA tissue was
obtained from consenting donors of similar age undergoing sur-
gery for benign pathology. No patient received chemotherapy
before surgery. Patient characteristics are described in Table I.
Brieﬂy, normal tissue was obtained by scraping epithelial cells
from the ovarian surface and placing them in RPMI-1640 medium
(Sigma, St. Louis, MO) containing 10% FBS (Invitrogen, Grand
Island, NY), 200 /ml penicillin and 200 g/ml streptomycin.
Epithelial explants were then allowed to attach and proliferate.
Once the epithelial cells reached conﬂuence, explants were
trypsinized and subcultured for 3 or 4 passages before being
collected for RNA extraction. Viable tumor tissue was mechani-
cally minced in RPMI-1640 to portions no larger than 1–3 mm3
and washed twice with RPMI-1640. Portions of minced tumor
were then placed into 250 ml ﬂasks containing 30 ml of enzyme
solution [0.14% collagenase type I (Sigma) and 0.01% DNAse
(Sigma, 2,000 KU/mg)] in RPMI-1640 and incubated in a mag-
netic stirring apparatus overnight at 4°C. Enzymatically dissoci-
ated tumor was then ﬁltered through 150 m nylon mesh to
generate a single-cell suspension. The resultant cell suspension
was then washed twice in RPMI-1640 plus 10% FBS. Primary cell
lines were maintained in RPMI-1640 supplemented with 10%
FBS, 200 /ml penicillin and 200 g/ml streptomycin at 37°C, 5%
CO2 in tissue culture ﬂasks (75–150 cm;2 Corning, Corning, NY).
Tumor cells were collected for RNA extraction at 50–80% con-
ﬂuence after 2–12 passages in vitro. The epithelial nature and
purity of OSPC and NOVA cultures were veriﬁed by immunohis-
tochemical staining and ﬂow-cytometric analysis with antibodies
against cytokeratin, as previously described.3,15 Only primary cul-
tures with at least 90% viability and 99% epithelial cells were
used for total RNA extraction.
RNA puriﬁcation and microarray hybridization and analysis
Detailed protocols for RNA puriﬁcation, cDNA synthesis,
cRNA preparation and hybridization to the Affymetrix (Santa
Clara, CA) Human U95Av2 GeneChip microarray were performed
according to the manufacturer’s protocols, as reported previously.18
Data processing
All data used were derived from Affymetrix 5.0 software.
GeneChip 5.0 output ﬁles are given as a signal that represents the
difference between the intensities of the sequence-speciﬁc perfect-
match probe set and the mismatch probe set or as detection of
present, marginal or absent signals as determined by the program’s
algorithm. Gene arrays were scaled to an average signal of 1,500
and then analyzed independently. Signal calls were transformed by
log base 2, and each sample was normalized to give a mean of 0
and variance of 1.
Gene expression data analysis
Statistical analyses of the data were performed with the software
package SPSS10.0 (SPSS, Chicago, IL) and the SAM method.19
Genes were selected for analysis based on detection and fold
change. In each comparison, genes having “present” detection
calls in more than half of the samples in the overexpressed group
were retained for statistical analysis if they showed a 2-fold
change between groups. Retained genes were subjected to SAM to
establish a FDR, then further ﬁltered via the WRS test at   0.05.
The FDR obtained from the initial SAM was assumed to charac-
terize genes found signiﬁcant via WRS.
Gene Cluster/Treeview
The hierarchical clustering of the average-linkage method with
the centered correlation metric was used.20 The dendrogram was
constructed with a subset of genes from 12,533 probe sets present
on the microarray, whose expression levels varied the most among
TABLE I – CHARACTERISTICS OF THE PATIENTS
Patient Age Race Grade Stage Presence of
ascites
Chemotherapy
regimen Response to therapy
OSPC 1 42 White G2/3 IVA yes TAXCARB Complete response
OSPC 2 67 White G3 IIIB yes TAXCARB Complete response
OSPC 3 61 White G3 IIIC no TAXCARB Partial response
OSPC 4 60 White G3 IIIC no TAXCARB Complete response
OSPC 5 59 Afro-American G2/3 IIIC yes TAXCARB Complete response
OSPC 6 72 White G3 IVA yes TAXCARB Stable disease
OSPC 7 63 White G3 IIIC yes TAXCARB Progressive disease
OSPC 8 74 Afro-American G2/3 IIIC no TAXCARB Partial response
OSPC 9 68 White G3 IIIB yes TAXCARB Complete response
OSPC 10 77 White G2/3 IIIC no TAXCARB Complete response
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the samples and were thus most informative. For the hierarchical
clustering shown in Figures 1 and 2, only genes signiﬁcantly
expressed and whose average change in expression level was at
least 5-fold were chosen. The expression value of each selected
gene was renormalized to a mean of 0.
Quantitative real-time PCR
Quantitative real-time PCR was performed with an ABI Prism
7000 Sequence Analyzer using the manufacturer’s recommended
protocol (Applied Biosystems, Foster City, CA) to validate differ-
ential expression of selected genes in samples from all 15 primary
cell lines. Each reaction was run in triplicate. The comparative Ct
method was used to calculate ampliﬁcation fold as speciﬁed by the
manufacturer. Brieﬂy, 5 g of total RNA from each sample were
reverse-transcribed using SuperScript II RNAse H Reverse Tran-
scriptase (Invitrogen, Carlsbad, CA). Reverse-transcribed RNA
samples (10 l, from 500 l of total volume) were ampliﬁed using
the TaqMan Universal PCR Master Mix (Applied Biosystems) to
produce PCR products speciﬁc for TROP-1, CD24, claudin 3 and
claudin 4. Primers speciﬁc for 18S ribosomal RNA and empiri-
cally determined ratios of 18S competimers (Applied Biosystems)
were used to control for the amounts of cDNA generated from
each sample. Primers for TROP-1, claudin 3 and claudin 4 were
obtained from Applied Biosystems as assay on demand products.
Assay IDs were Hs00158980_m1 (TROP-1), Hs00265816_s1
(claudin 3) and Hs00533616_s1 (claudin 4). CD24 primer se-
quences were as follows: forward, 5-cccaggtgttactgtaattcctcaa;
reverse, 5-gaacagcaatagctcaacaatgtaaac. Differences among
OSPC and NOVA samples in the quantitative real-time PCR
expression data were tested using the Kruskal-Wallis nonparamet-
ric test. Pearson product-moment correlations were used to esti-
mate the degree of association between the microarray and quan-
titative real-time PCR data.
Flow cytometry
To validate microarray data on primary OSPC and NOVA cell
lines at the protein level, TROP-1/EP-CAM and CD24 expression
were evaluated by ﬂow-cytometric analysis of a total of 13 primary
cell lines (i.e., 10 OSPC and 3 NOVA). Unconjugated anti-TROP-
1/EP-CAM (IgG2a), anti-CD24 (IgG2a) and isotype control (mouse
IgG2a) antibodies were obtained from BD Pharmingen (San Diego,
CA). Goat antimurine FITC-labeled mouse Ig was purchased from
Becton Dickinson (San Jose, CA). Analysis was conducted with a
FACScan, utilizing Cell Quest software (Becton Dickinson).
TROP-1 and CD24 immunostaining of formalin-ﬁxed tumor
tissues
To evaluate whether the differential TROP-1 and CD24 expres-
sion detected by ﬂow cytometry in primary OSPC cell lines was
comparable to the expression of TROP-1 and CD24 in uncultured
OSPC from which the primary cell lines were derived, protein
expression was evaluated by standard immunohistochemical stain-
ing on formalin-ﬁxed tumor tissue from all surgical specimens
(i.e., 10 OSPC and 5 NOVA controls). Study blocks were selected
after histopathologic review by a surgical pathologist. The most
representative hematoxylin and eosin–stained block sections were
used for each specimen. Brieﬂy, immunohistochemical stains were
performed on sections (4 m thick) of formalin-ﬁxed, parafﬁn-
embedded tissue. After pretreatment with 10 mM citrate buffer
(pH 6.0) using a steamer, sections were incubated with anti-Ep-
CAM Ab-3 and anti-CD24 MAbs (Neo Markers, Fremont, CA) at
1:2,000 dilution. Slides were subsequently labeled with strepta-
vidin–biotin (Dako, Glostrup, Denmark), stained with diamino-
benzidine and counterstained with hematoxylin. The intensity of
staining was graded as 0 (not greater than negative control), 1
(light), 2 (moderate) or 3 (heavy).
RESULTS
Gene expression proﬁles distinguish OSPC from NOVA and
identify differentially expressed genes
Flash-frozen biopsies from ovarian tumor tissue contain signif-
icant numbers of contaminant stromal cells as well as a variety of
host-derived immune cells (e.g., monocytes, dendritic cells, lym-
phocytes). In addition, because ovarian epithelial cells represent a
small proportion of the total cells found in the normal ovary, it is
difﬁcult to collect primary material that is free of contaminating
ovarian stromal cells in sufﬁcient quantities to conduct compara-
tive gene expression analyses. However, ovarian epithelial cells
can be isolated and expanded in culture for about 15 passages,3,6
while the majority of primary ovarian carcinomas can be expanded
in vitro for several passages.15 Thus, short-term primary OSPC and
NOVA cell cultures, minimizing the risk of selection bias inherent
in any long-term in vitro growth, may provide an opportunity to
study differential gene expression between relatively pure popu-
lations of normal and tumor-derived epithelial cells. Accordingly,
FIGURE 1 – Hierarchical clustering of 15 primary ovarian cell lines
(10 OSPC and 5 NOVA) and 2 established OSPC cell lines (UCI-101
and UCI-107).
FIGURE 2 – Molecular proﬁle of 10 primary OSPC and 5 NOVA cell
lines. Hierarchical clustering of 299 genes with differential expression
between 10 OSPC and 5 NOVA groups (p  0.05) using a 5-fold
threshold. The cluster is color-coded, using red for upregulation, green
for downregulation and black for median expression. Agglomerative
clustering of genes was illustrated with dendrograms.
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comprehensive gene expression proﬁles of 10 primary OSPC and
5 primary NOVA cell lines were generated using high-density
oligonucleotide arrays with 12,533 probe sets, which in total
included some 10,000 genes. In addition, gene expression proﬁles
derived from 2 established and previously characterized OSPC cell
lines (UCI-101 and UCI-107) were analyzed. By combining the
detection levels of genes signiﬁcantly expressed in primary and
established OSPC cultures, we found very little correlation be-
tween the 2 groups of OSPC. Indeed, as shown in Figure 1,
UCI-101 and UCI-107 cells grouped together in the dendrogram,
while all 10 primary OSPCs clustered tightly together in the
rightmost columns separate from the 5 NOVA controls. Because of
these results, we focused our analysis on the detection of differ-
entially expressed genes between the 2 homogeneous groups of
primary OSPC and NOVA cell lines. Figure 2 shows the cluster
analysis on hybridization intensity values for each gene in all 15
primary cultures of NOVA and OSPC. Using the nonparametric
WRS test (p  0.05), which readily distinguished between the 2
groups of primary cultures, we found 1,546 genes differentially
expressed between OSPC and NOVA. There were 365 genes
showing a 5-fold change along with “present” detection calls in
more than half the samples in the overexpressed group. Of these,
350 were signiﬁcant by SAM, with a median FDR of 0.35% and a
90th percentile FDR of 0.59%. Of the 365 genes, 299 yielded p 
0.05 via WRS and 298 were among those found signiﬁcant by
SAM. Figure 2 describes the cluster analysis performed on hybrid-
ization intensity values for 298 gene segments whose average
change in expression level was at least 5-fold and which were
signiﬁcant with both the WRS test and SAM. All 10 OSPCs were
grouped together in the rightmost columns. Similarly, in the left-
most columns, all 5 NOVA lines clustered tightly together. The
tight clustering of OSPC from NOVA lines was “driven” by 2
distinct proﬁles of gene expression. The ﬁrst was represented by a
group of 129 genes that were highly expressed in OSPC and
underexpressed in NOVA (Table II). Many genes shown previ-
ously to be involved in ovarian carcinogenesis are present on these
lists, providing some validity to our array analysis, while others are
novel in ovarian carcinogenesis. Included in these group of genes
are laminin, claudin 3, claudin 4, tumor-associated calcium signal
transducers 1 and 2 (TROP-1/Ep-CAM, TROP-2), ladinin 1,
S100A2, SERPIN2 (PAI-2), CD24, lipocalin 2, osteopontin, kal-
likrein 6 (protease M), kallikrein 10, matriptase (TADG-15) and
stratiﬁn (Table II). TROP-1/Ep-CAM, encoding for a transmem-
brane glycoprotein previously found to be overexpressed in vari-
ous carcinoma types including colorectal and breast21 and where
antibody-directed therapy has resulted in improved survival,22 was
39-fold differentially expressed in OSPC compared to NOVA
(Table II). The second proﬁle was represented by 170 genes that
were highly expressed in NOVA and underexpressed in OSPC
(Table III). Included in this group of genes are transforming
growth factor- receptor III, platelet-derived growth factor recep-
tor , SEMACAP3, ras homolog gene family member I (ARHI),
thrombospondin 2 and disabled-2/differentially expressed in ovar-
ian carcinoma 2 (Dab2/DOC2) (Table III).
Validation of microarray data
We used quantitative real-time PCR assays to validate the
microarray data. Four highly differentially expressed genes be-
tween OSPC and NOVA (i.e., TROP-1, CD24, claudin-3 and
claudin-4) were selected for quantitative real-time PCR analysis. A
comparison of the microarray and quantitative real-time PCR data
for these genes is shown in Figure 3. Expression differences
between OSPC and NOVA for TROP-1 (p  0.02), CD24 (p 
0.004), claudin 3 (p  0.02) and claudin 4 (p  0.01) were readily
apparent (Table II, Fig. 3). Moreover, for all 4 genes tested, the
quantitative real-time PCR data were highly correlated to the
microarray data (p  0.001; r  0.81, 0.90, 0.80 and 0.85, respec-
tively), as estimated from the samples (i.e., 10 OSPC and 5 NOVA)
included in both the quantitative real-time PCR and microarray ex-
periments. Thus, quantitative real-time PCR data suggest that most
array probe sets are likely to accurately measure the levels of the
intended transcript within a complex mixture of transcripts.
TROP-1 and CD24 expression by flow cytometry in primary
OSPC and NOVA cell lines
An important issue is whether differences in gene expression result
in meaningful differences in protein expression. Because the TROP-
1/Ep-CAM gene encodes the target for the anti-Ep-CAM antibody
(17-1A) edrecolomab (Panorex), which has previously been shown to
increase survival in patients harboring stage III colon cancer,22 ex-
pression of Ep-CAM protein by FACS analysis was analyzed in 13
primary cell lines (10 OSPC and 3 NOVA). As positive controls,
breast cancer cell lines (i.e., BT-474 and SK-BR-3; ATCC, Rockville,
MD) known to overexpress TROP-1/Ep-CAM were also studied.
High TROP-1/Ep-CAM expression was found in all 10 primary OSPC
cell lines tested (100% positive cells for all 10 OSPC), with MFI
ranging 116–280 (Fig. 4). In contrast, primary NOVA cell lines were
negative for TROP-1/Ep-CAM surface expression (p  0.001) (Fig.
4). Similarly, CD24 expression was found in all primary OSPC cell
lines tested (100% positive cells for all 10 OSPC), with MFI ranging
26–55 (Fig. 4). In contrast, primary NOVA cell lines were negative
for CD24 surface expression (p  0.005) (Fig. 4). These results show
that high expression of the TROP-1/Ep-CAM and CD24 gene prod-
ucts by OSPC correlates tightly with high protein expression by tumor
cells. Breast cancer-positive controls expressed high levels of TROP-
1/Ep-CAM (data not shown).
TROP-1/Ep-CAM and CD24 expression by immunohistology on
OSPC and NOVA tissue blocks
To determine whether the high (OSPC) or low (NOVA) expres-
sion of the genes and Ep-CAM and CD24 proteins detected by
microarray and ﬂow cytometry, respectively, in primary cell lines
was the result of selection of a subpopulation of cancer cells
present in the original tumor or whether in vitro expansion condi-
tions may have modiﬁed gene expression, we performed immu-
nohistochemical analysis of TROP-1/Ep-CAM and CD24 protein
expression on formalin-ﬁxed tumor tissue from all uncultured
primary surgical specimens of OSPC and NOVA. As shown in the
left panel of Figure 5, heavy apical membranous staining for CD24
protein expression was noted in all OSPC specimens that also
overexpressed the CD24 gene and its gene product by microarray
and ﬂow cytometry, respectively. In contrast, negative or low (i.e.,
score 0 or 1) staining was found in all NOVA samples tested by
immunohistochemistry. Similarly, as shown in the right panel of
Figure 5, heavy membranous staining for TROP-1/Ep-CAM pro-
tein expression (i.e., score 3) was noted in all OSPC specimens
that also overexpressed the TROP-1/Ep-CAM gene and its gene
product by microarray and ﬂow cytometry, respectively. In con-
trast, negative or low (i.e., score 0 or 1) staining was found in all
NOVA samples tested by immunohistochemistry.
DISCUSSION
Because of the lack of an effective ovarian cancer screening
program and the common development of chemotherapy-resistant
disease after an initial response to cytotoxic agents (i.e., platinum-
based regimen), ovarian cancer remains the most lethal among the
gynecologic malignancies.2 Thus, identiﬁcation of novel ovarian
tumor markers to be used for early detection of the disease as well
as the development of effective therapy against chemotherapy-
resistant/recurrent ovarian cancer remains a high priority.
High-throughput technologies for assaying gene expression,
such as high-density oligonucleotide and cDNA microarrays, may
offer the potential to identify clinically relevant genes highly
differentially expressed between ovarian tumors and NOVA con-
trol epithelial cells.3–11 Our investigation involved genomewide
examination of differences in gene expression between primary
OSPC and NOVA epithelial cells. We used short-term primary
OSPC and NOVA cultures (to minimize the risk of selection bias
inherent in any long-term in vitro growth) to study differential
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gene expression in highly enriched populations of epithelial tumor
cells. Only cancer cells derived from papillary serous histology tu-
mors, which is the most common histologic type of ovarian cancer,
were included, to limit the complexity of gene expression analysis.
We found that hierarchical clustering of samples and gene
expression levels within samples led to the unambiguous separa-
tion of OSPC from NOVA. Of interest, the expression patterns
detected in primary OSPC cells were consistently different from
those seen in established OSPC cell lines (i.e., UCI-101 and
UCI-107). These data, thus, further highlight the divergence of
gene expression that occurs as a result of long-term in vitro
growth. Furthermore, these data emphasize that, although estab-
lished ovarian cancer cell lines provide a relatively simple model
to examine gene expression, primary OSPC and NOVA cultures
TABLE II – UPREGULATED GENES EXPRESSED AT LEAST 5 FOLD HIGHER IN OSPC COMPARED WITH NOVA
Probe set Gene symbol Score(d)(SAM) p of WRS Ratio ova/nova Probe set Gene symbol Score(d)(SAM) p of WRS Ratio ova/nova
35280_at LAMC2 1.68927386 0.006 46.45
35276_at CLDN4 1.734410451 0.015 43.76
33904_at CLDN3 1.650076713 0.02 40.24
575_s_at TACSTD1 1.705816336 0.02 39.36
32154_at TFAP2A 1.667038647 0.002 33.31
39015_f_at KRT6E 1.062629117 0.047 28.02
1713_s_at CDKN2A 1.137682905 0.015 26.96
41376_i_at UGT2B7 0.939735032 0.047 24.81
38551_at L1CAM 1.151935363 0.008 24.66
291_s_at TACSTD2 1.249487388 0.047 24.46
33282_at LAD1 1.422481563 0.006 24.31
34213_at KIBRA 1.533570321 0.002 23.06
38489_at HBP17 1.522882814 0.004 22.54
36869_at PAX8 1.43906836 0.004 22.20
38482_at CLDN7 1.307716566 0.027 20.01
37909_at LAMA3 1.121654521 0.027 19.24
34674_at S100A1 1.219106334 0.008 19.01
1620_at CDH6 0.908193479 0.036 18.69
32821_at LCN2 1.99990601 0.008 18.13
522_s_at FOLR3 1.113781518 0.02 17.90
39660_at DEFB1 0.837612681 0.036 17.34
2011_s_at BIK 1.594057668 0.006 17.23
41587_g_at FGF18 0.965726983 0.02 17.10
36929_at LAMB3 1.115590892 0.047 16.76
35726_at S100A2 1.036576352 0.004 15.05
1887_g_at WNT7A 1.186990893 0.004 14.75
35879_at GAL 1.223278825 0.002 14.65
266_s_at CD24 1.756569076 0.004 14.45
1108_s_at EPHA1 1.242309171 0.006 14.36
37483_at HDAC9 1.406744957 0.006 14.28
31887_at — 1.311220827 0.011 13.68
1788_s_at DUSP4 1.22421987 0.003 13.65
32787_at ERBB3 0.996784565 0.02 13.21
41660_at CELSR1 1.634286803 0.004 13.11
33483_at NMU 1.100849065 0.004 13.04
31792_at ANXA3 0.896090153 0.011 12.90
36838_at KLK10 1.026306829 0.02 12.71
1585_at ERBB3 1.102058608 0.011 12.51
1898_at TRIM29 1.071987353 0.002 12.44
37185_at SERPINB2 0.815945986 0.027 12.26
406_at ITGB4 1.296194559 0.006 11.66
1914_at CCNA1 0.9363427778 0.011 11.21
977_s_at CDH1 0.93637461 0.036 11.19
37603_at IL1RN 1.103624942 0.015 11.14
35977_at DKK1 1.123240701 0.006 10.74
36133_at DSP 1.280269127 0.002 10.69
36113_s_at TNNT1 1.269558595 0.002 10.19
1802_s_at ERBB2 0.787465706 0.006 9.61
2092_s_at SPP1 1.34315986 0.02 9.53
35699_at BUB1B 1.026388835 0.006 9.49
37554_at KLK6 0.895036336 0.027 9.45
38515_at BMP7 0.945367 0.027 9.32
34775_at TSPAN-1 1.001195829 0.02 9.01
37558_at IMP-3 1.023799379 0.011 8.99
38324_at LISCH7 1.308000521 0.006 8.96
39610_at HOXB2 1.355268631 0.006 8.64
572_at TTK 1.122796615 0.006 8.53
1970_s_at FGFR2 1.022708001 0.02 8.30
160025_at TGFA 1.065272755 0.015 8.28
41812_s_at NUP210 1.39287031 0.006 8.26
34282_at NFE2L3 1.165273649 0.008 8.06
2017_s_at CCND1 1.114984456 0.002 8.04
33323_r_at SFN 1.202433185 0.008 8.01
38766_at SRCAP 1.131917941 0.008 7.99
41060_at CCNE1 1.151246634 0.006 7.97
39016_r_at KRT6E 0.973486831 0.008 7.91
31610_at MAP17 1.0156502 0.027 7.81
2027_at S100A2 0.941919001 0.008 7.76
418_at MKI67 0.826426448 0.011 7.46
1536_at CDC6 1.08868941 0.017 7.37
634_at PRSS8 0.899891713 0.02 7.30
34342_s_at SPP1 1.318723271 0.02 7.27
182_at ITPR3 1.107167336 0.006 7.27
32382_at UPK1B 0.731294678 0.047 7.16
863_g_at SERPINB5 0.783530451 0.015 7.14
904_s_at TOP2A 0.971648429 0.02 7.12
40095_at CA2 0.798857154 0.027 7.02
41294_at KRT7 1.082553892 0.011 7.00
39951_at PLS1 0.995091449 0.006 6.94
38051_at MAL 0.819842532 0.036 6.82
40726_at KIF11 0.803689697 0.036 6.78
1148_s_at — 0.683569558 0.047 6.72
37920_at PITX1 0.996497645 0.015 6.67
37117_at ARHGAP8 1.129131077 0.002 6.65
38881_i_at TRIM16 0.721698355 0.047 6.59
34251_at HOXB5 1.219463307 0.002 6.52
41359_at PKP3 1.047269618 0.004 6.50
40145_at TOP2A 0.961173129 0.02 6.48
37534_at CXADR 0.888147605 0.006 6.32
40303_at TFAP2C 0.948734146 0.004 6.30
31805_at FGFR3 0.969764101 0.011 6.28
33245_at MAPK13 0.877514586 0.011 6.27
885_g_at ITGA3 0.702747685 0.036 6.19
34693_at STHM 0.872525584 0.008 6.15
38555_at DUSP10 0.880305317 0.008 6.12
38418_at CCND1 1.071102249 0.002 5.97
33730_at RAI3 0.813298748 0.011 5.90
39109_at TPX2 1.040973216 0.011 5.87
36658_at DHCR24 1.122129795 0.004 5.81
35281_at LAMC2 0.747766326 0.047 5.78
38749_at MGC29643 0.683275086 0.036 5.77
1083_s_at MUC1 0.746980491 0.027 5.75
40079_at RAI3 0.709840659 0.02 5.73
2047_s_at JUP 0.815282235 0.011 5.62
32275_at SLPI 0.940625784 0.02 5.61
2020_at CCND1 0.926408163 0.002 5.51
33324_s_at CDC2 1.026683994 0.008 5.47
36863_at HMMR 0.96343264 0.006 5.46
1657_at PTPRR 0.764510362 0.02 5.41
37985_at LMNB1 0.895475347 0.008 5.36
36497_at C14orf78 0.942921564 0.008 5.33
2021_s_at CCNE1 0.893228297 0.006 5.33
37890_at CD47 0.775908217 0.015 5.33
40799_at C16orf34 0.852774782 0.008 5.30
35309_at ST14 0.852534105 0.008 5.30
1599_at CDKN3 0.925527261 0.02 5.29
981_at MCM4 1.058558782 0.006 5.28
32715_at VAMP8 0.938171642 0.006 5.28
38631_at TNFAIP2 0.72369235 0.015 5.26
34715_at FOXM1 1.31035831 0.008 5.24
33448_at SPINT1 0.924028022 0.015 5.21
419_at MKI67 0.938133197 0.015 5.16
1651_at UBE2C 1.436239741 0.008 5.14
35769_at GPR56 0.937347548 0.015 5.08
37310_at PLAU 0.885110741 0.036 5.08
36761_at ZFN339 0.937123503 0.011 5.05
37343_at ITPR3 1.001079303 0.003 5.05
40425_at EFNA1 0.813414458 0.047 5.04
1803_at CDC2 0.732852195 0.027 5.00
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TABLE III – UPREGULATED GENES EXPRESSED AT LEAST 5 FOLD HIGHER IN NOVA COMPARED WITH OSPC
Probe set Gene symbol Score(d)(SAM) p of WRS Ratio ova/nova Probe set Gene symbol Score(d)(SAM) p of WRS Ratio ova/nova
39701_at PEG3 1.991111245 0.006 113.32
32582_at MYH11 1.921434447 0.002 67.31
39673_i_at ECM2 1.740409609 0.011 53.54
37394_at C7 1.597329897 0.02 50.45
37247_at TCF21 2.261979734 0.002 39.29
1897_at TGFBR3 1.648143277 0.003 38.12
36627_at SPARCL1 1.610346382 0.008 37.84
37015_at ALDH1A1 1.886579474 0.002 35.18
38469_at TM4SF3 1.620821878 0.003 34.43
35717_at ABCA8 1.709820793 0.008 33.92
32664_at RNASE4 1.720857082 0.003 32.94
40775_at ITM2A 1.393751125 0.006 31.35
38519_at NR1H4 1.431579641 0.004 27.02
37017_at PLA2G2A 1.263990266 0.011 26.68
36681_at APOD 1.44030134 0.008 26.04
34193_at CHL1 1.738491852 0.006 25.97
34363_at SEPP1 1.490374268 0.015 25.93
1501_at IGF1 1.116943817 0.027 25.87
33240_at SEMACAP3 1.818843975 0.003 25.54
36939_at GPM6A 0.924236354 0.047 25.47
614_at PLA2G2A 1.391395227 0.003 23.15
37407_s_at MYH11 1.72766007 0.002 22.73
39325_at EBAF 1.248164036 0.02 22.49
767_at — 1.688001805 0.002 21.90
37595_at — 1.582101386 0.004 20.94
1290_g_at GSTM5 1.383630361 0.003 20.84
34388_at COL14A1 1.400078214 0.015 20.39
607_s_at VWF 1.314435559 0.002 19.05
37599_at AOX1 1.669903577 0.003 17.61
41504_s_at MAF 1.463988429 0.008 16.40
41412_at PIPPIN 1.799353403 0.002 16.08
279_at NR4A1 1.194733065 0.008 15.42
38427_at COL15A1 1.570514035 0.002 15.38
41405_at SFRP4 1.478603828 0.002 14.44
39066_at MFAP4 1.91469237 0.004 14.26
1731_at PDGFRA 1.791307012 0.003 13.91
36595_s_at GATM 1.382271028 0.004 13.86
34343_at STAR 2.080476608 0.003 13.67
36917_at LAMA2 1.359731285 0.006 13.51
38430_at FABP4 1.054221974 0.02 13.05
36596_r_at GATM 1.22177547 0.008 12.67
35898_at WISP2 1.276226302 0.004 12.55
36606_at CPE 1.608244463 0.003 12.30
32057_at LRRC17 1.345223643 0.011 12.22
33431_at FMOD 1.516795166 0.003 12.17
34985_at CILP 0.905018335 0.02 11.53
755_at ITPR1 1.433938835 0.002 11.06
1466_s_at FGF7 1.184028604 0.027 11.00
36727_at — 0.98132702 0.036 10.96
1103_at RNASE4 1.456068199 0.002 10.88
32666_at CXCL12 1.342426238 0.006 10.72
914_g_at ERG 1.264721284 0.002 10.54
40698_at CLECSF2 1.325237675 0.002 10.46
36873_at VLDLR 1.344197327 0.004 10.45
1090_f_at — 0.914708216 0.027 10.34
36042_at NTRK2 0.950553444 0.02 10.32
36311_at PDE1A 1.356950738 0.004 10.21
41685_at NY-REN-7 0.8848466 0.036 10.08
32847_at MYLK 1.545610138 0.002 10.00
35358_at TENC1 1.539140855 0.003 9.97
32249_at HFL1 1.257702238 0.02 9.86
36695_at na 1.452847153 0.003 9.82
1987_at PDGFRA 1.50655467 0.002 9.76
37446_at GASP 1.219014593 0.004 9.76
35752_s_at PROS1 1.211272096 0.008 9.66
36533_at PTGIS 1.882348646 0.004 9.62
38886_i_at ARHI 1.127672988 0.02 9.59
36733_at FLJ32389 1.420588897 0.011 9.57
38717_at DKFZP586A0522 1.158933663 0.015 9.50
32551_at EFEMP1 1.385495033 0.004 9.38
1968_g_at PDGFRA 1.364848071 0.003 9.31
33910_at PTPRD 1.129963902 0.008 9.20
32778_at ITPR1 1.370809534 0.002 9.08
280_g_at NR4A1 1.074894321 0.006 8.79
35389_s_at ABCA6 1.209294071 0.011 8.79
32889_at RPIB9 1.145333813 0.003 8.74
37248_at CPZ 1.238797022 0.002 8.69
39674_r_at ECM2 0.874009817 0.027 8.67
33911_at PTPRD 1.099609918 0.02 8.66
35234_at RECK 1.407865518 0.008 8.58
32119_at — 1.153957574 0.011 8.57
35998_at LOC284244 1.104281231 0.008 8.54
37279_at GEM 1.012760866 0.008 8.31
35702_at HSD11B1 1.164189513 0.004 8.28
32126_at FGF7 1.336918337 0.008 8.22
36867_at — 1.273166453 0.008 8.21
38653_at PMP22 1.422063697 0.002 8.19
38875_r_at GREB1 1.026886865 0.015 8.10
35366_at NID 1.483421362 0.002 8.10
34417_at FLJ36166 0.783978445 0.047 7.98
37221_at PRKAR2B 0.927090765 0.036 7.91
39031_at COX7A1 1.564725491 0.004 7.89
39757_at SDC2 1.288106392 0.002 7.80
36629_at DSIPI 0.981563882 0.008 7.79
35390_at ABCA6 1.026714913 0.036 7.79
39629_at PLA2G5 1.405181995 0.002 7.70
40961_at SMARCA2 0.996692724 0.015 7.68
719_g_at PRSS11 1.399043078 0.002 7.65
40856_at SERPINF1 1.077533093 0.008 7.55
37008_r_at SERPINA3 1.134224016 0.002 7.53
33834_at CXCL12 1.060878451 0.002 7.51
31880_at D8S2298E 1.177864913 0.002 7.45
37628_at MAOB 1.194963489 0.004 7.43
34853_at FLRT2 1.250330254 0.027 7.41
38887_r_at ARHI 1.169953614 0.015 7.32
38220_at DPYD 1.024334451 0.02 7.26
1327_s_at MAP3K5 0.891703475 0.02 7.23
1380_at FGF7 1.096254206 0.004 7.14
37573_at ANGPTL2 1.052539345 0.002 7.08
718_at PRSS11 1.381205346 0.002 6.99
36712_at — 1.15195149 0.005 6.88
1709_g_at MAPK10 1.160327795 0.002 6.85
39123_s_at TRPC1 1.060327922 0.015 6.79
38627_at HLF 0.911787462 0.036 6.79
32076_at DSCR1L1 1.127515982 0.002 6.77
36669_at FOSB 1.023057503 0.011 6.65
38194_s_at IGKC 1.239936045 0.015 6.64
39545_at CDKN1C 1.040717569 0.004 6.62
36993_at PDGFRB 1.384657766 0.004 6.60
35837_at SCRG1 1.023840456 0.036 6.48
1507_s_at EDNRA 1.23933124 0.004 6.48
40488_at DMD 1.291791538 0.002 6.42
38364_at — 1.030881108 0.004 6.35
41424_at PON3 0.946224951 0.036 6.32
32109_at FXYD1 1.005577422 0.004 6.19
1182_at PLCL1 1.097390316 0.002 6.17
31897_at DOC1 1.533672652 0.003 6.13
37208_at PSPHL 1.007759699 0.015 6.08
36396_at — 1.009684807 0.015 6.07
41505_r_at MAF 1.116101319 0.006 6.06
37765_at LMOD1 1.127716375 0.003 6.00
37398_at PECAM1 0.970664041 0.008 5.98
41013_at FLJ31737 1.036561659 0.003 5.98
39279_at BMP6 1.106724571 0.002 5.93
1527_s_at CG018 0.804755548 0.047 5.91
39038_at FBLN5 1.279283798 0.004 5.89
32542_at FHL1 1.134214637 0.002 5.88
38508_s_at TNXB 0.878513741 0.011 5.74
32696_at PBX3 0.888011703 0.027 5.69
41796_at PLCL2 0.857601993 0.02 5.68
34473_at TLR5 0.871815246 0.027 5.67
661_at GAS1 1.267909476 0.004 5.66
41449_at SGCE 1.050056933 0.004 5.65
35740_at EMILIN1 1.366368794 0.011 5.58
37908_at GNG11 0.989043327 0.004 5.43
37406_at MAPRE2 1.265872665 0.002 5.41
33802_at HMOX1 1.034088234 0.015 5.41
39106_at APOA1 1.266005754 0.008 5.40
1771_s_at PDGFRB 1.336082701 0.006 5.39
39409_at C1R 1.05784087 0.011 5.39
32535_at FBN1 1.422415283 0.006 5.35
37710_at MEF2C 0.98149558 0.011 5.35
37958_at TM4SF10 1.293658009 0.003 5.35
33756_at AOC3 0.829203515 0.02 5.29
36569_at TNA 0.926096917 0.006 5.25
39771_at RHOBTB1 1.048906896 0.008 5.20
39852_at SPG20 0.82401517 0.027 5.20
35168_f_at COL16A1 1.509830282 0.011 5.18
33244_at CHN2 0.92878389 0.015 5.18
35681_r_at ZFHX1B 1.170745794 0.006 5.14
2087_s_at CDH11 1.656534188 0.008 5.12
40496_at C1S 0.973175912 0.011 5.10
41137_at PPP1R12B 1.12885067 0.008 5.07
39698_at HOP 0.797252583 0.011 5.05
38211_at ZNF288 0.926263264 0.015 5.04
41839_at GAS1 1.127093791 0.006 5.03
39979_at F10 0.890787173 0.002 5.02
1135_at GPRK5 1.150554994 0.002 5.01
479_at DAB2 1.255638531 0.006 5.01
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represent a better model system of normal and cancerous ovarian
tissues in comparative gene expression analysis. Because of these
results, we focused our analysis on the detection of differentially
expressed genes between the 2 homogeneous groups of primary
OSPC and NOVA.
We detected 298 genes differentially expressed between OSPC
and NOVA whose average change in expression level between the
2 groups was at least 5-fold and which were signiﬁcant with both
the WRS test and SAM. The known function of some of these
genes may provide insights in the biology of serous ovarian
tumors, while others may prove to be useful diagnostic and ther-
apeutic markers against OSPC. For example, the laminin 2 gene
was the most highly differentially expressed gene in OSPC, with
over 46-fold upregulation relative to NOVA. Migration of ovarian
epithelial cells is considered essential for cell dissemination and
invasion of the submesothelial extracellular matrix commonly seen
FIGURE 3 – Quantitative real-
time PCR and microarray expres-
sion analyses of TROP-1, CD24,
claudin 3 and claudin 4 genes dif-
ferentially expressed between
OSPC and NOVA.
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in ovarian cancer. Consistent with this view, the laminin 2
isoform has been previously suggested to play an important role in
the adhesion, migration and scattering of ovarian carcinoma
cells.23–25 Thus, it is likely that the high laminin expression found
in ovarian tumor cells may be a marker correlated with the inva-
sive potential of OSPC. Consistent with this view, increased cell
surface expression of laminin has been reported in highly meta-
static tumors cells compared to cells of low metastatic potential.26
Previous work has also shown that attachment and metastasis of
tumor cells can be inhibited by incubation with antilaminin anti-
bodies27 or synthetic laminin peptides,28 underscoring the novel
potential for the treatment of chemotherapy-resistant ovarian can-
cer.
TROP-1/Ep-CAM (also called 17-1A, ESA, EGP40) is a 40 kDa
epithelial transmembrane glycoprotein overexpressed in several
normal epithelia and in various carcinomas, including colorectal
and breast cancers.21 In most adult epithelial tissues, enhanced
expression of Ep-CAM is closely associated with either benign or
malignant proliferation. Among mammals, Ep-CAM is an evolu-
tionarily highly conserved molecule,29 suggesting an important
biologic function in epithelial cells and tissue. In this regard,
Ep-CAM is known to function as an intercellular adhesion mole-
cule and could have a role in tumor metastasis.30 Because a
randomized phase II trial with MAb CO17-1A in colorectal car-
cinoma patients has demonstrated a signiﬁcant decrease in recur-
rence and mortality of MAb-treated patients vs. controls,22 TROP-
1/Ep-CAM antigen has attracted substantial attention as a target
for immunotherapy in human carcinomas. In our work, TROP-1/
Ep-CAM was 39-fold differentially expressed in OSPC compared
to NOVA. These data support the notion that anti-Ep-CAM anti-
body therapy may be a novel and potentially effective treatment
option for OSPC patients with residual/resistant disease after sur-
FIGURE 4 – Representative FACS
analysis of CD24 staining (left
panel) and TROP-1/Ep-CAM stain-
ing (right panel) of 2 primary
OSPC cell lines and 1 NOVA cell
line. Data on CD24 and TROP-1/
Ep-CAM are shown in solid black,
while isotype control MAb proﬁles
are shown in white. Expression of
both CD24 and TROP-1/Ep-CAM
was signiﬁcantly higher in OSPC
compared to NOVA cell lines (p 
0.001 by Student’s t-test).
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gical and cytotoxic therapy. Protein expression data obtained by
ﬂow cytometry on primary OPSC cell lines and by immunohisto-
chemistry on uncultured OSPC blocks support this view.
Claudin 3 and claudin 4, 2 members of claudin family of tight
junction proteins, were 2 of the top 5 differentially expressed genes
in OSPC. These results are consistent with a previous report on
gene expression in ovarian cancer.6 Although the function of
claudin proteins in ovarian cancer remains unclear, they likely
represent a transmembrane receptor.31 Of interest, claudin 3 and
claudin 4 are homologous to CPE-R, the low- and high-afﬁnity
intestinal epithelial receptors for CPE, respectively, and are sufﬁ-
cient to mediate CPE binding and trigger subsequent toxin-medi-
FIGURE 5 – Representative immunohistochemical staining for CD24 (left panel) and Trop-1/Ep-CAM (right panel) markers of 2 parafﬁn-
embedded OSPC specimens and 1 NOVA specimen. NOVA 1 (upper panel, right and left) showed negative or light (1) staining for both CD24
and Trop-1/Ep-CAM, while OSPC 1 and OSPC 3 showed heavy apical membranous staining for CD24 (lower and middle panel, left) and strong
membranous staining for TROP-1/Ep-CAM (right). Original magniﬁcation 400.
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ated cytolysis.32 These known functions of claudin 3 and claudin
4 combined with their extremely high level of expression in OSPC
have suggested the use of CPE as a novel therapeutic strategy to
treat chemotherapy-resistant disease in ovarian cancer patients.
Supporting this view, the functional cytotoxicity of CPE in meta-
static, androgen-independent prostate cancer overexpressing clau-
din 3 has been reported.33
PAI-2, a gene whose expression has been linked to cell invasion
in several human malignancies34,35 as well as to protection from
TNF--mediated apoptosis,36 was 12-fold differentially expressed
in OSPC compared to NOVA. Consistent with our ﬁndings, pre-
vious studies have shown that elevated levels of PAI-2 are detect-
able in the ascites of ovarian cancer patients and that high PAI-2
levels are independently predictive of poor disease-free surviv-
al.37,38 In some of these studies, a 7-fold increase in PAI-2 content
was found in the omentum of ovarian cancer patients compared to
primary disease, suggesting that metastatic tumors may overex-
press PAI-2.38 Other studies, however, have identiﬁed PAI-2 pro-
duction as a favorable prognostic factor in epithelial ovarian can-
cer.39 Indeed, high PAI-2 expression in invasive ovarian tumors
was limited to a group of OSPC patients who experienced more
prolonged disease-free and overall survival.39 The reasons for
these differences are not clear but, as previously suggested,40 may
be related at least in part to the actions of macrophage colony
stimulating factor-1, a cytokine which stimulates the release of
PAI-2 by ovarian cancer cells.
CD24 is a small, heavily glycosylated glycosylphosphatidyl-
inositol-linked cell surface protein, which is expressed in hemato-
logic malignancies as well as in a large variety of solid tu-
mors.41–46 However, it is only recently that CD24 overexpression
has been reported at the RNA level in ovarian cancer.4 Consistent
with this report, we found the CD24 gene to be 14-fold differen-
tially expressed in OSPC compared to NOVA. Because CD24 is a
ligand of P-selectin, an adhesion receptor on activated endothelial
cells and platelets, its expression may contribute to the metastatic
capacities of CD24-expressing ovarian tumor cells.47–49 CD24
expression has been reported to be an independent prognostic
marker for ovarian cancer patient survival.50 These data combined
with our ﬁndings further suggest that this marker may delineate
aggressive ovarian cancer disease and may be targeted for thera-
peutic and/or diagnostic purposes.
Among the genes we have identiﬁed, to the best of our knowl-
edge, lipocalin 2 has not been previously linked to ovarian cancer.
Lipocalin 2 represents a particularly interesting marker because of
several features. Lipocalins are extracellular carriers of lipophilic
molecules, such as retinoids, steroids and fatty acids, all of which
may play important roles in the regulation of epithelial cell
growth.51,52 In addition, because lipocalin is a secreted protein, it
may play a role in the regulation of cell proliferation and sur-
vival.51,52 Of interest, 2 publications, on gene expression proﬁling
of breast and pancreatic cancers, have proposed lipocalin 2 as a
novel therapeutic and diagnostic marker for prevention and treat-
ment of these diseases.53,54 On the basis of our ﬁndings, lipocalin
2 may be added to the known markers for ovarian cancer.
Osteopontin (SPP1) is an acidic, calcium-binding glycophos-
phoprotein that has been linked to tumorigenesis in several exper-
imental animal models and human patient studies.55–57 Because of
its integrin-binding, arginine-glycine-aspartate domain and adhe-
sive properties, osteopontin has been reported to play a crucial role
in the metastatic process of several human tumors.55,58 However, it
is only recently that the upregulated expression of osteopontin in
ovarian cancer has been identiﬁed.59 Because of the secreted
nature of this protein, osteopontin has been proposed as a novel
biomarker for the early recognition of ovarian cancer.59 In our
study, the SPP1 gene was 10-fold differentially expressed in OSPC
compared to NOVA. Taken together, these data conﬁrm a high
expression of osteopontin in OSPC and further suggest that future
research assessing its clinical usefulness in ovarian cancer would
be worthwhile.
The organization of kallikreins, a gene family consisting of 15
genes that encode for trypsin-like or chymotrypsin-like serine
proteases, has been elucidated.60 Serine proteases have well-char-
acterized roles in diverse cellular activities, including blood coag-
ulation, wound healing, digestion and immune responses, as well
as tumor invasion and metastasis (reviewed by Diamandis and
Yousef60). Because of the secreted nature of some of these en-
zymes, prostate-speciﬁc antigen and kallikrein 2 have already
found important clinical application as prostate cancer biomark-
ers.60 Of interest, kallikrein 6 (also known as zyme/protease
M/neurosin), kallikrein 10 and matriptase (TADG-15/MT-SP1)
were highly differentially expressed in OSPC compared to NOVA.
These data conﬁrm previous results from our group as well as
others showing high expression of several kallikrein genes and
proteins in ovarian neoplasms.60–64 Moreover, these results, ob-
tained by high-throughput technologies for assaying gene expres-
sion, further emphasize the view that some members of the kal-
likrein family have the potential to become novel cancer markers
for early diagnosis of ovarian cancer64 as well as targets for novel
therapies against recurrent/refractory ovarian disease.65 Other
highly ranked genes in OSPC included stratiﬁn, desmoplakin,
S100A2, cytokeratin 6, cytokeratin 7 and MUC-1.
A large number of downregulated (at least 5-fold) genes in
OSPC vs. NOVA, such as transforming growth factor beta recep-
tor III, platelet-derived growth factor receptor , SEMACAP3, ras
homolog gene family member I (ARHI), thrombospondin 2 and
disabled-2/differentially expressed in ovarian carcinoma 2 (Dab2/
DOC2) (Table III), were identiﬁed in our analysis. Some encode
for widely held tumor-suppressor genes, such as SEMACAP3,
ARHI and Dab2/DOC2,66 and others for proteins important for
ovarian tissue homeostasis or previously implicated in apoptosis,
proliferation, adhesion or tissue maintenance. Because of space
limitations, we will not comment further on the cluster of genes
that showed downregulation of the transcripts in invasive tumors.
In conclusion, several OSPC-restricted markers have been iden-
tiﬁed through our analysis. Some of these genes have been previ-
ously reported to be highly expressed in ovarian cancer, while
others have not been linked with this disease. Finally, identiﬁca-
tion of TROP-1/Ep-CAM and CPE epithelial receptors as some of
the most highly differentially expressed genes in OSPC compared
to NOVA suggests that novel therapeutic strategies targeting
TROP-1/Ep-CAM by MAbs22 and/or claudin 3 and claudin 4 by
local and/or systemic administration of CPE33 may represent novel
therapeutic modalities in patients harboring OSPC refractory to
standard treatment.
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